Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recently emerged
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …
pathogenic human coronavirus that belongs to the sarbecovirus lineage of the genus …
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …
Structural biology of SARS-CoV-2 and implications for therapeutic development
H Yang, Z Rao - Nature Reviews Microbiology, 2021 - nature.com
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for …
(SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for …
The humoral response and antibodies against SARS-CoV-2 infection
Two and a half years into the COVID-19 pandemic, we have gained many insights into the
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …
human antibody response to the causative SARS-CoV-2 virus. In this Review, we …
[HTML][HTML] Neutralizing monoclonal antibodies for treatment of COVID-19
PC Taylor, AC Adams, MM Hufford… - Nature Reviews …, 2021 - nature.com
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
[HTML][HTML] Antibody evasion by the P. 1 strain of SARS-CoV-2
Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates …
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates …
Tools and techniques for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/COVID-19 detection
SUMMARY The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory disease coronavirus 2 (SARS-CoV-2), has led to millions of confirmed cases and …
respiratory disease coronavirus 2 (SARS-CoV-2), has led to millions of confirmed cases and …
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …
vaccines and have received emergency use authorization as therapeutics. However, viral …
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
AB Vogel, I Kanevsky, Y Che, KA Swanson, A Muik… - Nature, 2021 - nature.com
A safe and effective vaccine against COVID-19 is urgently needed in quantities that are
sufficient to immunize large populations. Here we report the preclinical development of two …
sufficient to immunize large populations. Here we report the preclinical development of two …